



9 October 2017 1 2 EMA/118465/2012 Rev 1* - Track-change version following public consultation

Guideline on good pharmacovigilance practices (GVP) 3

Module XV – Safety communication (Rev 1) 4

Date for coming into effect of first version	24 January 2013
Draft Revision 1* finalised by the Agency in collaboration with Member States	17 November 2015
Draft Revision 1 agreed by the European Risk Management Facilitation Group (ERMS FG)	24 November 2015
Draft Revision 1 adopted by Executive Director	8 December 2015
Release for consultation	15 December 2015
End of consultation (deadline for comments)	29 February 2016
Revised draft Revision 1 finalised by the Agency in collaboration with Member States	27 September 2017
Revised draft Revision 1 agreed by the EU Network Pharmacovigilance Oversight Group (EU-POG)	4 October 2017
Revised draft Revision 1 adopted by Executive Director as final*	9 October 2017
Date for coming into effect of Revision 1**	13 October 2017

5

This track-change version identifies the majority of changes introduced to the public consultation 6 7 version of this document as the Agency's response to the comments received from the public 8 consultation. This track-change version is published for transparency purposes and must not be taken 9 or quoted as the final version. * For this reason, the timetable above, and in particular the date of coming into effect, apply only the 10 11 clean version published as final.

- For the final version of this module and any future updates, please see the GVP webpage of the 12 13 Agency's website.
- 14

15 *Note: Revision 1 contains the following:

- Introduction of the concept of core EU DHPC for situations where a common DHPC prepared at EU 16
- level may not be appropriate because of different requirements at the level of Member States (e.g. 17

European Medicines Agency www.ema.europa.eu Heads of Medicines Agencies www.hma.eu

The European Medicines Agency is an agency of the European Union



© European Medicines Agency and Heads of Medicines Agencies, 2017. Reproduction is authorised provided the source is acknowledged.

See websites for contact details

- differences in available alternative treatments) and the PRAC/CHMP therefore agrees on core messages
 only (changes in XV.A., XV.B.2., XV.C.2.1. and XV.C.2.2.);
- 20 Introduction of the option that one marketing authorisation holder may act on behalf of other
- 21 marketing authorisation holders with a goal of disseminating one single DHPC in situations where 22 several marketing authorisation holders are concerned (changes in XV.C.2.2.);
- Adjustments of references to other GVP Modules, given the recently revised GVP structure (see page
 6 of GVP Introductory Note of 15 December 2015);
- Editorial improvements throughout the Module (changes in particular in XV.A., XV.B.2., XV.B.3,
 XV.B.5., XV.B.5.1., XV.B.5.2., XV.B.6., XV.C.1., XV.C.1.1., XV.C.1.2.);
- 27 The revised GVP Annex II DHPC template (EMA/36988/2013) and the new GVP Annex II DHPC
- 28 Communication Plan template (EMA/334164/2015) have been replicated at the end of the Module for29 ease of reference.
- 30 After the public consultation, the of outcome of work package 2 on communication and dissemination
- 31 of the Strengthening Collaboration for Operating Pharmacovigilance in Europe (SCOPE) Joint Action of
- 32 <u>the Member States (see www.scopejointaction.eu) have become available and have been incorporated</u>
 33 <u>to the Module.</u>
- 34

35 <u>Note for public consultation</u>:

- 36 The public consultation is restricted to the yellow highlighted revised texts (i.e. replaced by new texts
- 37 with deletions and additions) or deleted texts (i.e. not replaced). However, if revisions or deletions
- 38 impact or contradict other existing text, comments on such non-highlighted texts will be processed and
- taken into account for the finalisation process. Comments on the GVP Annex II templates should be
- 40 provided separately (see EMA/36988/2013 and EMA/334164/2015).
- 41
- 42

43 Table of contents

44	XV.A. Introduction	. 4
45	XV.B. Structures and processes	. 5
46	XV.B.1. Objectives of safety communication	5
47	XV.B.2. Principles of safety communication	5
48	XV.B.3. Target audiences	6
49	XV.B.4. Content of safety communication	7
50	XV.B.5. Means of safety communication	7
51	XV.B.5.1. Direct healthcare professional communication (DHPC)	8
52 53	XV.B.5.2. Communication materials from competent authorities targeted at healthcare professionals	9
54	XV.B.5.3. Documents in lay language to patients and the general public	9
55	XV.B.5.4. Press communication	10
56	XV.B.5.5. Website	
57	XV.B.5.6. Social media and other online communications	
58	XV.B.5.7. Bulletins and newsletters	
59	XV.B.5.8. Inter-authority communication	
60	XV.B.5.9. Responding to enquiries from the public	
61	XV.B.5.10. Other means of communication	
62	XV.B.6. Effectiveness of safety communication	
63	XV.B.7. Quality system requirements for safety communication	12
64	XV.C. Operation of the EU regulatory network	12
65	XV.C.1. Coordination of safety announcements in the EU	12
66	XV.C.1.1. Process for exchange and coordination of safety announcements	13
67	XV.C.1.2. Exchange of safety information produced by third parties	14
68	XV.C.1.3. Requirements for the marketing authorisation holder in the EU	
69	XV.C.1.4. Consideration for third parties	
70	XV.C.1.5. Languages and translations	
71	XV.C.2. Direct healthcare professional communications in the EU	
72	XV.C.2.1. Processing of DHPCs	
73	XV.C.2.2. Translation and dissemination of DHPCs	
74	XV.C.2.3. Publication of DHPCs	
75 76	Figure XV.1: Flow chart for the processing of Direct Healthcare Professional Communicatio (DHPCs) in the EU.	
77 78	GVP Annex II – Templates: Direct Healthcare Professional Communication	
79 80	GVP Annex II – Templates: Communication Plan for Direct Healthcare Professional Communication	21

81

82 XV.A. Introduction

This Module provides guidance to marketing authorisation holders, competent authorities in Member 83 84 States and the European Medicines Agency on how to communicate and coordinate safety information 85 concerning medicinal products authorised in the EU, in particular to support achieving the quality objectives of pharmacovigilance. Communicating safety information to patients and healthcare 86 professionals is a public health responsibility and is essential for achieving the objectives of 87 pharmacovigilance in terms of promoting the rational, safe and effective use of medicines, preventing 88 89 harm from adverse reactions and contributing to the protection of patients' and public health 90 Communicating safety information to patients and healthcare professionals is a public health responsibility and is essential for achieving the objectives of pharmacovigilance in terms of promoting 91 the rational, safe and effective use of medicines, preventing harm from adverse reactions, minimising 92 93 risks and contributing to the protection of patients' and public health (see GVP Module I). 94 Safety communication is a broad term covering different types of information on medicines, including statutory information as contained in the product information (i.e. the summary of product 95 96 characteristics (SmPC), package leaflet (PL) and the labelling of the packaging) and public assessment 97 reports. Although some principles in this Module (i.e. XV.B.1 and XV.B.2.) apply to all types of safety 98 communication, the Module itself focuses on the communication of 'important new-or emerging safety 99 information', which means new information about a previously known or unknown risk of a medicine 100 which has or may-could have an impact on a medicine's risk-benefit balance and its condition of use. 101 Unless otherwise stated, the term 'safety communication' in this Module should be read as referring to 102 newemerging safety information. 103 Experience so far has demonstrated the need to coordinate safety communication within the EU 104 regulatory network. High levels of public interest are anticipated when new safety concerns arise and it 105 is important that clear and consistent messages are provided across the EU in a timely manner. The 106 new legislation on pharmacovigilance therefore includes a number of provisions to strengthen safety 107 communication and its coordination¹. 108 Communication of important new safety information on medicinal products should take into account 109 the views and expectations of concerned parties, including patients and healthcare professionals, with 110 due consideration given to relevant legislation. This Module addresses some aspects of the interaction 111 with concerned parties. 112 -and supplements the specific guidance given in GVP Module XI on public participation as well as the guidance on communication planning in relation to safety-related action given in GVP Module XII. 113 114 Communication, which in this Module refers to the active dissemination of safety information with for an 115 intended audience, is distinct from transparency. Transparency, which aims to provide public access to 116 information related to data assessment, decision-making and safety monitoring performed by 117 competent authorities. The new EU legislation on pharmacovigilance envisages an unprecedented level 118 of transparency. Transparency provisions applicable to each pharmacovigilance process are provided in 119 the relevant GVP Modules. 120 XV.B. of this Module describes principles and means of safety communication. XV.C. provides guidance 121 on the coordination and dissemination of safety communications within the EU network. Both sections give particular consideration to direct healthcare professional communications (DHPCs), and provide 122 123 specific guidance for preparing them. This is because of the central importance of DHPCs in targeting

¹ Directive 2010/84/EU amending Directive 2001/83/EC (the latter is referenced as DIR), Regulation (EU) No 1235/2010 amending Regulation (EC) No 726/2004 (the latter is referenced as REG) and in the Commission Implementing Regulation (EU) No 520/2012 on the Pperformance of Ppharmacovigilance Aactivities Pprovided for in Regulation (EC) No 726/2004 and Directive 2001/83/EC (the Implementing Regulation is referenced as IR).

- healthcare professionals and because of the level of coordination required between marketing
 authorisation holders and competent authorities in their preparation. <u>The same principles also apply to</u>
 proactive communications by competent authorities.
- 127 Throughout this Module, legal obligations are referred to as stated in the GVP Introductory Cover Note
- and are usually identified by the modal verb 'shall' (e.g. 'the marketing authorisation holder shall').
- When guidance is provided on how to implement legal provisions, the modal verb 'should' is used (e.g.'the marketing authorisation holder should').

131 <u>In particular i</u>In Section B, the term "competent authority" is to be understood in its generic meaning
 132 of an authority regulating medicinal products and/or an authority appointed at national level for being
 133 in charge of all or individual pharmacovigilance processes. For the purpose of applying GVP in the EU,

134 <u>+The term "competent authority" covers the relevant competent authorities in the EU Member States</u>
135 <u>and the Agency.</u>

136 XV.B. Structures and processes

137 XV.B.1. Objectives of safety communication

- 138 Safety communication aims at:
- providing timely, evidence-based information on the safe and effective use of medicines;
- facilitating changes to healthcare practices (including self-medication practices) where necessary;
- changing attitudes, decisions and behaviours in relation to the use of medicines;
- 142 supporting risk minimisation behaviour;
- facilitating informed decisions on the rational use of medicines.

144 In addition to the above effective, high_-quality safety communication can support public confidence in 145 the regulatory system.

146 XV.B.2. Principles of safety communication

- 147 The following principles of safety communication should be applied:
- Safety communication should deliver relevant, clear, accurate and consistent messages and reach
 the right audiences at the right time for them to take appropriate action.
- Safety communication should be tailored to the appropriate audiences (e.g. patients and healthcare professionals) by using appropriate language and taking account of the different levels of knowledge and information needs whilst maintaining the accuracy and consistency of the information conveyed.
- The need for communicating safety information should be considered throughout the
 pharmacovigilance and risk management process, and should be part of <u>the risk assessment and</u>
 risk minimisation measures. the considering options for safety-related action risk assessment (see
 GVP Module XII).
- There should be adequate coordination and cooperation between the different parties involved in
 issuing safety communications (e.g. competent authorities, other public bodies and marketing
 authorisation holders).

161 162	•	-Safety communication should deliver relevant, clear, accurate and consistent messages and reach the right audiences at the right time for them to take appropriate action.	
163 164 165 166 167	•	<u>Safety communication should be tailored to the appropriate audiences (e.g. patients and healthcare professionals) by using appropriate language and taking account of the different levels of knowledge and information needs whilst maintaining the accuracy and consistency of the information is a specific definition of the different levels information conveyed.</u>	
168 169 170	•	Information on risks should be presented in the context of the benefits of the medicine and include available and relevant information on the seriousness, severity, frequency, risk factors, time to onset, reversibility of potential adverse reactions and, if available, expected time to recovery.	
171 172 173 174	•	Safety communication should address the uncertainties related to a safety concern. This is of particular relevance for <u>newemerging</u> information which is often communicated while competent authorities are conducting their evaluations; the usefulness of communication at this stage needs to be balanced against the potential for confusion if uncertainties are not properly represented.	
175 176	•	Information on competing risks such as the risk of non-treatment should be included where appropriate.	
177 178 179 180	•	The most appropriate quantitative measures should be used when describing and comparing risks, e.g. the use of absolute risks and not just relative risks; for risk comparisons when comparing risks, denominators should be the same in size. The use of other tools such as graphical presentation of the risk and/or the risk-benefit balance may also be used_considered.	
181 182	•	Patients and healthcare professionals should, where possible, be consulted and messages pre- tested early in the preparation of safety communication, particularly on complex safety concerns.	
183 184	•	Where relevant safety communication should be complemented at a later stage with follow-up communication e.g. on the resolution of a safety concern or updated recommendations.	
185 186	•	The effectiveness of safety communication should be evaluated where appropriate and possible (see XV.B.7.).	
187 188	•	Safety communications should comply with relevant requirements relating to individual data protection and confidentiality.	
189	XI	/.B.3. Target audiences	
190 191 192	ma	e primary target audiences for safety communication issued by regulatorycompetent authorities and Irketing authorisation holders should be patients, <mark>carers</mark> and healthcare professionals who use (i.e. escribe, handle, dispense, administer or take) medicinal products.	
193 194 195 196 197 198	As primary target audiences, healthcare professionals play an essential role in ensuring that medicines are used as <u>effectively and safely as possible</u> . Effective safety communication enables them to <u>take</u> <u>adequate actions to minimise risks and to give clear and useful information to their patients</u> , <u>which</u> . <u>This ultimately thereby</u> -promotesing patient safety and confidence in the regulatory system. Both healthcare professionals in clinical practice and those involved in clinical trials should be provided with appropriate information on any safety concern at the same time.		
199	Pat	tient, consumer and healthcare professional organisations can play a role as multipliers as they can	

200 disseminate important safety information to target audiences.

The media is also a target audience for safety communication. The capacity of the media to reach out to patients, healthcare professionals and the general public is a critical element for amplifying new and important information on medicines. The way safety information is communicated through the media will influence the public perception and it is therefore important that the media receives safety information directly from the competent authorities in addition to the information they receive from other sources, such as from the marketing authorisation holders.

207 XV.B.4. Content of safety communication

208	The information in the safety communication shall not be misleading and shall be presented objectively				
209	[DIR Art 106a(1)]. Safety information should not include any material or statement which might				
210	constitute advertising within the scope of Title VIII of Directive 2001/83/EC.				
211 212	<u>Therefore, t</u> Faking into account the <u>above provisions and the principles in XV.B.2.</u> , safety communication should contain:				
213	 important <u>newemerging</u> information on any authorised medicinal product which has an impact on				
214	the medicine's risk-benefit balance under any conditions of use;				
215	 the reason for initiating safety communication clearly explained to the target audience; 				
216 217	 any recommendations to healthcare professionals and patients on how to deal with a safety concern; 				
218	 when applicable, a statement on the agreement between the marketing authorisation holder and				
219	the competent authority on the safety information provided;				
220	 information on any proposed change to the product information (e.g. the summary of product				
221	characteristics (SmPC) or package leaflet (PL));				
222	 any additional information about the use of the medicine or other data that may be relevant for				
223	tailoring the message to the targeted audience;				
224 225	• a list of literature references, when relevant or a reference to where more detailed information can be found, and any other background information considered relevant;				
226 227	• where relevant, a reminder of the need to report suspected adverse reactions in accordance with national spontaneous reporting systems.				
228	The information in the safety communication shall not be misleading and shall be presented objectively				
229	[DIR Art 106a(1)]. Safety information should not include any material or statement which might				
230	constitute advertising within the scope of Title VIII of Directive 2001/83/EC.				
231	XV.B.5. Means of safety communication				

 $^{^{2}}$ For the purpose of this Section tools and channels are presented without distinction as they often overlap and there is no general agreement on their categorisation.

237 XV.B.5.1. Direct healthcare professional communication (DHPC)

A direct healthcare professional communication (DHPC) is defined in this document as as a
 communication intervention by which important safety information is delivered directly to individual

healthcare professionals by a marketing authorisation holder or a competent authority, to inform them of the need to take certain actions or adapt their practices in relation to a medicinal product. DHPCs are not replies to enquiries from healthcare professionals. τ

- 243 nor are they meant as educational material for routine risk minimisation activities.
- The preparation of DHPCs involves cooperation between the marketing authorisation holder and the competent authority. Agreement between these two parties should be reached before a DHPC is issued by the marketing authorisation holder. The agreement will cover both the content of the information DHPC (see XV.B.4.) and the communication plan (see GVP Annex II), including the intended recipients. and the timetable and the communication tools and channels for disseminating the DHPC.
- Where there are several marketing authorisation holders of the same active substance <u>and/or a class</u>
 of products for which a DHPC is to be issued, a single consistent message should normally be
 delivered-(see XV.C.2.1).
- Whenever possible <u>and appropriate</u>, it is advised that healthcare professionals' organisations or learned
 societies are involved as appropriate during the preparation of DHPCs to ensure that the information
 <u>delivered by the they-DHPCs- deliver</u> is useful and adapted to the target audience.
- A DHPC <u>should</u> be complemented by other communication tools and channels and the principle of providing consistent information should apply (XV.B.2.).
- A DHPC <u>should be included as may be an additional risk minimisation measure as part of a risk</u> management plan (see GVP Modules V and XVI).
- A DHPC should be disseminated in the following situations when there is a need to take immediate action or change current practice in relation to a medicinal product:
- suspension, withdrawal or revocation of a marketing authorisation for safety reasons;
- an important change to the use of a medicine due to the restriction of an indication, a new
 contraindication, or a change in the recommended dose due to safety reasons;
- a restriction in availability or discontinuation of a medicine with potential detrimental effects on
 patient care.
- 266 Other situations where dissemination of a DHPC should be considered are:
- new major warnings or precautions for use in the product information;
- new data identifying a previously unknown risk or a change in the frequency or severity of a known
 risk;
- substantiated knowledge new evidence that the medicinal product is not as effective as previously
 considered;
- new recommendations for preventing or treating adverse reactions or to avoid misuse or medication errors with the medicinal product;
- ongoing assessment of an important potential risk, for which data available at a particular point in time are insufficient to take regulatory action (in this case, the DHPC should encourage close monitoring of the safety concern in clinical practice and encourage reporting, and possibly provide information on how to minimise the potential risk).

A competent authority may disseminate or request the marketing authorisation holder to disseminate a
DHPC in any situation where the competent authority considers it necessary for the continued safe and
effective use of a medicinal product.

281 XV.B.5.2. Communication materials from competent authorities targeted at 282 healthcare professionals

- 283 Competent authorities can issue safety communications targeting healthcare professionals directly. These are usually published on the website of the competent authority. These communications are 284 285 issued in parallel and often complement other means for communicating a safety concern (e.g. a DHPC) and are issued aroundt the same time. They contain the competent authority's 286 287 recommendations and advice for risk minimisation for healthcare professionals-in relation to the safety 288 concern, and provide relevant background information. Adequate links to further information can be 289 included (e.g. links to the product information of the concerned medicinal product(s) and, whenever 290 possible, prescription and dispensing systems).
- Safety communications from competent authorities should follow the principles identified above (see
 XV.B.2.) and should be issued when there is a need to take immediate action or change current
 practice in relation to a medicinal product (see XV.B.5.1.).Competent authorities should also consider
 existing public interest when issuing a safety communication.
- 295 <u>Whenever possible and appropriate, it is advised that healthcare professionals are involved during the</u>
 296 <u>preparation of the safety communication to ensure that the information the safety</u>
 297 communicationscontained deliver is useful and adapted to the target audience.
- 298 Competent authorities should make use of the most appropriate tools and channels described in this
 299 Section to maximise dissemination and accessibility of relevant information. This includes interaction
 300 with other organisations such as learned societies, local health authorities, patient and other
 301 healthcare organisations, as appropriate.

302 XV.B.5.23. Documents in lay language to patients and the general public

- Communication material in lay language (e.g. using a questions & answers format) helps patients and the general public to understand the scientific evidence and regulatory actions relating to a safety concern. It can <u>also also helpbe an additional tool that</u> healthcare professionals <u>can use in theirto</u> communication-e-better with their-patients. Lay language documents should contain the competent authority's recommendations and advice for risk minimisation for patients- and healthcare professionals in relation to the safety concern, <u>_</u> and should be accompanied by relevant background information.
- Lay language documents are generallyshould be -useful to members of the public who have an interest
 in the subject but do not have a scientific or regulatory background. Reference should be made to
 other communication materials on the topic to direct readers to where they can find further
 information.
- For the dissemination and accessibility of lay language documents, the most appropriate tools and
 channels described in this Section should be used as appropriate.
- 315 Whenever possible and appropriate, it is advised that patients and healthcare professionals are
- 316 involved during the preparation of lay language documents to ensure that the information they deliver
- 317 is useful and adapted to the target audience.

318 XV.B.5.34. Press communication

Press communication includes press releases and press briefings which are primarily intended forjournalists.

321 Competent authorities may send press releases directly to journalists in addition to publishing them on

- their websites. This ensures that journalists, in addition to obtaining information from other sources,
 receive information that is consistent with the authority's scientific assessment. Interaction with the
- media is an important way to reach out to a wider audience as well as to build trust in the regulatorysystem.
- Press releases may also be prepared and published by marketing authorisation holders. Their press releases may reflect the position of the marketing authorisation holder on a safety topic but should also make reference to <u>any-the</u> regulatory action taken by the competent authority. Relevant ongoing reviews should be mentioned in any communication by the marketing authorisation holder.
- Although aimed at journalists, press releases will be read by other audiences such as healthcare professionals, patients and the general public. Reference should therefore be made to related communication materials on the topic. In cases where a DHPC <u>and/or a communication from a</u> competent <u>authority is</u> also prepared, healthcare professionals should ideally receive it prior to or around the same time of the publication or distribution of a press release so that they are better prepared to respond to patients.
- Press briefings with journalists should be considered by competent authorities for safety concerns or
 other matters relating to the safety of medicinal products that are of high media interest or when
 complex or public-health-sensitive messages need to be conveyed.

339 XV.B.5.4<u>5</u>. Website

A website is a key tool for members of the public (including patients and healthcare professionals) actively searching the internet for specific information on medicinal products. Competent authorities as well as marketing authorisation holders should ensure that important safety information published on websites under their control is easily accessible and understandable by the public. Information on websites should be kept up-to-date, with any information that is out-of-date marked as such or removed.

The <u>new-applicable</u> legislation on pharmacovigilance foresees the creation of an EU medicines web portal which will contain information on all medicines authorised in the EU [REG Art 26(1)]. This web portal will become a key tool for communicating up-to-date safety information to EU citizens and will contain information in all EU official languages. Each Member State shall set up and maintain a national medicines web-portal which shall be linked to the EU medicines web-portal- [DIR Art 106a]. Until the web portal is fully established and into operation, the Agency's website will be acting as an interim platform to convey this important up-to-date safety information.

353 XV.B.5.<u>6</u>5. <u>Social media and Oo</u>ther <u>web-basedonline</u> communications

Online safety information may also be disseminated via <u>social media and other</u> web tools. When using
 newer, more rapid communication channels, special attention should be paid to ensure that the
 accuracy of the information released is not compromised. Communication practices should take into
 account emerging <u>digital</u> communication tools used by the various target audiences.

358 XV.B.5.76. Bulletins and newsletters

Bulletins and newsletters provide at regular intervals-new information about medicines and their safety
 and effectiveness. <u>These tools may serve as reminders of previous communications.</u> Competent
 authorities can reach a large audience with these tools by using web-based and other available means.

362 XV.B.5.87. Inter-authority communication

When one competent authority takes regulatory action on a particular safety concern, other competent authorities <u>usually-may also receive need to respond to enquiries or may want to</u>-communicate on the same issue. The use of inter-authority communication material, such as lines-to-take should be considered. Lines-to-take are documents specifically-prepared by a competent authority to assist its own-staff and those of co-operating authorities in responding <u>consistently</u> to external enquires or communicating <u>a consistent message</u> on a specific safety issue.

369 XV.B.5.<u>98</u>. Responding to enquiries from the public

Competent authorities and marketing authorisation holders should have systems in place for responding to enquiries about medicines from individual members of the public. Responses should take into account the information which is in the public domain and should include the relevant recommendations to patients and healthcare professionals issued by competent authorities. Where questions relate to individual treatment advice, the patient should be advised to contact a healthcare professional.

In this respect, <u>DIR</u> Articles 86(2) and <u>Article-98(1) of Directive 2001/83/EC</u> apply to marketing
 authorisation holders.

378 XV.B.5.109. Other means of communication

In addition to those discussed above, there are other tools and channels such as publications inscientific journals and journals of professional bodies.

Some tools and channels may be used in the context of risk management; <u>in addition to the product</u>
 information of the medicinal product, <u>so-called</u> other communication tools can be used to disseminate
 information about the product. These are considered as additional risk minimisation measures often
 and may include_specific programmes for risk communication. Tools used in such programmes, <u>tools</u>
 such as patient alert cards or healthcare professional safety guidanceeducational materials., <u>etc</u> These
 are outside the scope of this Module and are described in more detail in GVP Module XVI.

387 XV.B.6. Effectiveness of safety communication

388 Safety communication is considered effective when the message transmitted is received and 389 understood by the target audience in the way it was intended, and appropriate action is taken by the 390 target audience. Adequate Where possible, mechanisms should be introduced in order to measure the 391 effectiveness of the communication based on clear objectives. Measuring effectiveness allows lessons 392 to be learned and helps in making decisions on prioritising and adapting tools and practices to meet 393 the needs of the target audiences. A research-based approach will normally be appropriate in order to 394 establish that safety communications have met the standard of XV.B.2.- This approach may measure 395 different outcomes, including behaviour, attitudes, and knowledge. When evaluating the effectiveness 396 of safety communication, the scope of the evaluation may be broadened to include factors other than 397 the performance of the individual tools used in the safety communication (see GVP Module XVI).

- 398 In the case of DHPCs, the marketing authorisation holders should be responsible for evaluating the
- 399 dissemination of the DHPCs they prepare and should inform the relevant competent authorities about
- 400 the number of healthcare professionals reached who received the DHPC and about any of encountered
- 401 difficultyies identified- during the dissemination of the DHPCs the outcome and of any difficulties
- 402 **identified** (e.g. problems related to the list of recipients or the timing and mechanism of
- dissemination). Appropriate action should be taken as needed to correct the situation or prevent
- similar problems in the future.

405 XV.B.7. Quality system requirements for safety communication

406 In accordance with the quality system requirements in GVP Module I, procedures should be in place to 407 ensure that safety communications comply with the principles in XV.B.2. as appropriate.

In particular, the safety communications should be subject to quality controls to ensure their accuracy
and clarity. For this purpose review procedures with allocated responsibilities should be followed and
documented.

411 **XV.C. Operation of the EU regulatory network**

412 XV.C.1. Coordination of safety announcements in the EU

- 413 In the EU, patients and healthcare professionals increasingly look at competent authorities as providers
- 414 of important information on medicines. For safety communication to be effective, adequate
- 415 coordination and cooperation is required within the EU regulatory network³. A good level of
- 416 coordination of safety communication is of particular importance so that healthcare professionals and
- 417 patients receive consistent information on regulatory decisions in the EU.
- When issuing safety announcements, competent authorities may make use of the different tools and channels described in XV.B.5. Prior to the publication of a safety announcement, the Member States, the Agency or the European Commission shall inform each other not less than 24 hours in advance,
- 421 unless urgent public announcements are required for the protection of public health [DIR Art 106a(2)].
- For active substances contained in medicinal products authorised in more than one Member State, the
 Agency shall be responsible for the coordination between national competent authorities of safety
 announcements and shall provide timetables for the information being made public [DIR Art 106a(3)].
- 425 For practical reasons, considering the potential for overlap between transparency measures and active 426 communications and in order to focus on those topics of major health relevance, not all safety
- information made public by a Member State or the Agency will be subject to systematic exchange and
 coordination. Only safety announcements that relate to the following and that pertain to active
 substances contained in medicinal products authorised in more than one Member State require
- 430 coordination within the EU regulatory network:
- 431 the suspension, withdrawal or revocation of a marketing authorisation due to changes to its risk432 benefit balance;
- 433 _____the start or finalisation of an EU referral procedure for safety reasons;
- + restriction of indication or treatment population or the addition of a new contraindication that may
 + have a major impact on the use of a medicine;
- 436

•

³ i.e. the competent authorities in the Member States, the Agency and the European Commission.

- 437 dissemination of a DHPC <u>which concerns an active substance authorised in more than one Member</u>
 438 <u>State agreed by relevant competent authorities of a Member State or the Agency</u> (see XV.C.2.1.);
- other emerging safety concerns judged by a national competent authority or the Agency to be
 likely to give rise to public or media interest in more than one Member State (e.g. a publication of
 important safety findings in a (scientific) journal, safety-related regulatory action taken in a
 Member State or in a country outside the EU).

443 XV.C.1.1. Process for exchange and coordination of safety announcements

- 444 A competent authority of a Member State or the Agency shall inform the EU regulatory network prior to 445 the publication of a safety announcement that pertains to active substances contained in medicinal 446 products authorised in more than one Member State and that refer to any of the situations identified in 447 XV.C.1. It shall include a timetable for the information being made public [DIR Art 106a(3)]. Whenever 448 possible the safety announcement shall be sent to the network under embargo not less than 24 hours 449 in advance of prior to the publication [DIR Art 106a-(2)], in order to allow the members of the EU 450 regulatory network to prepare or plan their own communication, if necessary. Under the coordination 451 of the Agency, the Member States shall make all reasonable efforts to agree on a common message in 452 relation to the safety of the medicinal product concerned and the timetables for the distribution [DIR 453 Art 106a(3)].
- 454 The Agency, together with the relevant Member State(s) who originated the process and the PRAC
 455 <u>Lead Member State or the PRAC Rapporteur, as appropriate</u>, should decide for each case, on the basis
- of the public health relevance and urgency of the safety concern, the population and number of
 Members States affected and the potential for media attention, whether further communication action
- 458 in addition to the dissemination of the safety announcement is needed, such as:
- the preparation of lines-to-take (see XV.B.5.7.) for dissemination to the EU regulatory network.
 The lines-to-take document should help the EU regulatory network to respond to any request for
 information which may follow the publication of the safety announcement;
- the preparation of an Agency safety announcement in addition to that of the Member State, which
 should also be disseminated under embargo to the EU regulatory network together with a
 timetable for its publication.
- The Agency should prepare lines-to-take documents and any Agency safety announcement together with the Member State(s) who originated the process and the PRAC Lead Member State or the PRAC Rapporteur, as appropriate. The PRAC, as well as the CHMP or CMDh, should also be consulted as necessary.

Coordination of safety announcements should be done in cooperation with the concerned marketing
authorisation holder(s). Whenever possible, the Agency and the competent authorities in the Member
States should provide any safety announcement prior to its publication to the concerned marketing
authorisation holder(s), together with the timetable for the information being made public. Any
information of a personal or commercially confidential nature shall be deleted unless its public
disclosure is necessary for the protection of public health [DIR Art 106a-(4)].
The exchange and coordination of safety announcements within the EU regulatory network should

476 make use of the EU Early Notification System (ENS). The ENS was developed for use by the Agency to
477 provide advance notice to competent authorities in Member States and the European Commission of
478 safety information on centrally authorised products. This system should also be used by competent
479 authorities in Member States for the purpose of exchanging and coordinating safety announcements.
480 The ENS includes the Heads of Medicines Agencies (HMA), the members of the PRAC, CHMP, <u>PDCO</u>,

481 CMDh, the operational contact points for safety announcements at the competent authority in <u>the</u>
482 Member States, the European Commission and the Agency. Operational contact points should ensure
483 that any information exchanged via the system reaches in a timely manner the relevant staff within
484 each competent authority, including relevant staff working within the communications departments.

Safety announcements from the EU regulatory network should be shared with international partners in accordance with the guidance provided in GVP Module XIV, subject to embargo and any specific
 confidentiality arrangements in place.

As a complement to the coordination of safety announcements within the EU regulatory network, competent authorities in Member States and the Agency should interact with concerned stakeholders in the EU (mainly patients' and healthcare professionals' organisations), who can play a key role in reviewing and disseminating information to the end users (patients and healthcare professionals). It is recommended that national competent authorities and the Agency keep up-to-date contact details of relevant patients'₇ and healthcare professionals' organisations.

494 XV.C.1.2. Exchange of safety information produced by third parties

There are situations where <u>emerging-new</u> safety information is to be published or has been published by a party other than a competent authority of a Member State or the Agency (e.g. scientific journals, learned societies). Competent authorities should bring to the attention of the EU regulatory network any such safety information that they become aware of, together with the timing of the publication if known. Where necessary and after evaluation of the information, the Agency should prepare and disseminate a lines-to-take document or an Agency safety announcement to address the information from the third party (see XV.C.1.1.).

In the context of collaboration with authorities outside the EU, the Agency or a competent authorityies
 of a Member State may become aware of safety announcements to be published by these authorities
 outside the EU (see GVP Module XIV). In these cases the Agency should, as necessary, prepare and
 disseminate lines-to-take or safety announcements within the EU regulatory network. In all cases, the
 terms of any relevant confidentiality agreements with non-EU regulatory authorities and the
 embargoes on the information received should be respected.

508 XV.C.1.3. Requirements for the marketing authorisation holder in the EU

509 As soon as a marketing authorisation holder in the EU intends to make a public announcement relating 510 to information on pharmacovigilance concerns in relation to the use of a medicinal product, and in any 511 event at the same time or before the public announcement is made, the marketing authorisation 512 holder shall be required to inform the competent authorities in the Member States, the Agency and the 513 European Commission [DIR Art 106a]. This should apply to announcements intended for the EU as well 514 as outside the EU (when they concern medicinal products authorised in the EU or those for which an 515 opinion under REG Article 58 of Regulation (EC) 726/2004 has been given). Informing the competent 516 authorities at the same time as the public (i.e. without advance notice to the competent authorities) 517 should only occur exceptionally and under justified grounds. Whenever possible, the information should

- be provided under embargo at least 24 hours prior to its publication.
- 519 The marketing authorisation holder shall ensure that information to the public is presented objectively 520 and is not misleading [DIR Art 106a].
- 521 Whenever a marketing authorisation holder becomes aware that a third party (see XV.C.1.2.) intends 522 to issue communications that could potentially impact the risk-benefit balance of a medicinal product
- authorised in the EU, the marketing authorisation holder should inform the relevant competent

authorities in Member States and the Agency and make every effort to share the content of thecommunications with the relevant <u>competent</u> authorities.

526 XV.C.1.4. Consideration for third parties

527 Third parties (e.g. <u>editors of scientific journals</u>, learned societies, patients' organisations) are

528 encouraged to inform the Agency and the competent authorities in <u>the</u> Member States of any relevant

529 <u>emerging new information on the safety of medicines authorised in the EU and, if publication is</u>

530 planned, to share the information ahead of publication.

531 XV.C.1.5. Languages and translations

532 Consistent messages should reach the public across the EU in a timely manner and in the official 533 languages of the Member States as specified by the Member States where the medicinal product is

- 534 placed on the market.
- 535 For the purpose of coordination, the Agency shall use English to inform the EU regulatory network of
- 536 any safety announcement. When informing the Agency, the competent authorities in the Member
- 537 States are encouraged to provide English translations of their safety announcements for the purpose of
- 538 initiating the coordination process<u>within the network</u>. In the absence of a full text translation, an
- 539 English summary should be provided.

540 XV.C.2. Direct healthcare professional communications in the EU

541 In the EU, a direct healthcare professional communication (DHPC) (see XV.B.5.1.) is usually

disseminated by one or a group of marketing authorisation holders for the respective medicinal

543 product(s) or active substance(s), either at the request of a national competent authority or the

Agency, or on the marketing authorisation holder's own initiative. The marketing authorisation holder

- should seek the agreement of the relevant national competent authorities or the Agency regarding the
- 546 content of a DHPC (and communication plan) (see GVP Annex II) prior to dissemination.

547 XV.C.2.1. Processing of DHPCs

- 548 The situations when a DHPC is necessary or should be considered are provided in XV.B.5.1. When 549 drafting a DHPC, the template (see GVP Annex II) and the guidance provided in the annotations in the 550 template should be followed as appropriate.
- 551 The roles and responsibilities of the competent authorities in a Member State, the Agency and 552 marketing authorisation holders in the preparation and processing of DHPCs depend on the route of 553 authorisation of the medicinal products concerned:
- for centrally authorised <u>medicinal</u> products and for <u>medicinal</u> products subject to an EU referral procedure for safety reasons, the relevant marketing authorisation holders should submit the draft
 DHPC and communication plan (including the intended recipients and the timetable for disseminating the DHPC) (see GVP Annex II) to the Agency, which should coordinate the review
 process by its scientific committees (i.e. PRAC and CHMP) and CMDh.
- for <u>medicinal</u> products authorised through the mutual recognition or decentralised procedure, the marketing authorisation holder should submit the draft DHPC and communication plan to the Reference Member State, which should co-ordinate the process with the marketing authorisation holder, while keeping the <u>Concerned Member States</u> ininvolved in the process.formed of any proposed action.

 for <u>purely</u> nationally authorised <u>medicinal</u> products-not authorised through the mutual recognition or decentralised procedure, the marketing authorisation holder should submit the draft DHPC and any communication plan to the competent authorities of the Member States where the <u>medicinal</u> products are authorised.

The marketing authorisation holder should allow a minimum of two working days for comments <u>during</u>
 the review. However, whenever possible, more time should be allowed. The timing may be adapted
 according to the urgency of the situation.

571 The Agency will coordinate the review of DHPCs within its scientific committees/groups as appropriate 572 (i.e. involvement of PRAC, and finalisation by CHMP or CMDh<u>as relevant</u>). The PRAC should always be 573 involved in the review of DHPCs related to a safety concern being discussed at the PRAC and the DHPC 574 should form part of the PRAC assessment assessment considerations of options for safety-related

- 575 action (see GVP Module XII). The Agency may also request advice from the PRAC on issues related to
- 576 other safety communications.
- 577 There might be situations where a single DHPC prepared at EU level may not be suitable as there may 578 be differences in Member States (such as differences in available therapeutic alternatives) which 579 cannot be addressed in a single DHPC. In such cases, it is proposed that a core EU DHPC is agreed at 580 EU level setting out core EU messages. The core EU DHPC can then be complemented at national level 581 with additional information to address the different national situations (for example i.e. in relation to 582 availability and choice of alternative treatments).
- 583 Although there will be national tailoring of such DHPCs, any core messages agreed at EU level should 584 should be preserved (i.e. tailoring should not conflict with these core messages).
- 585 In each Member State, when several marketing authorisation holders are concerned (i.e. when the DHPC covers several products with the same active substance or products of the same therapeutic 586 class), marketing authorisation holders are strongly encouraged to arrange for one marketing 587 588 authorisation holder to act on behalf of all concerned marketing authorisation holders as the contact 589 point for the national competent authority. Where generics are involved, the contact point should 590 normally be the marketing authorisation holder of the originator product. If no originator product is 591 marketed in a Member State, it is encouraged that one of the concerned generic companiesy it is 592 encouraged to acts as the contact point. Such coordination between concerned marketing authorisation 593 holders aims to ensure that healthcare professionals in a given Member State receive a single DHPC 594 covering all the medicinal products affected by a single safety concern (same active substance or a class review). The marketing authorisation holder acting as contact point for the national competent 595 596 authority and on behalf of all others marketing authorisation holders should be included specified in the
- 597 agreed communication plan (see GVP Annex II) to facilitate coordination.

598 Once the content of a DHPC and communication plan from the marketing authorisation 599 holder are agreed by national competent authorities or the Agency, the national competent authorities or the Agency should exchange share the final DHPC and communication plan 600 using the early notification system (see XV.C.1.1.), and the Agency or the national 601 602 competent authority as relevant should coordinate any subsequent safety announcement as appropriate using the process described in XV.C.1.1. The early notification system is only 603 used if the DHPC concerns an active substance authorised in more than one Member State. 604 605 In cases where an authority outside the EU requests the dissemination of a DHPC in their territory for a 606 medicinal product also authorised in the EU, the marketing authorisation holder should notify the 607 relevant competent authorities in the EU. This is part of the legal requirement under which the 608 marketing authorisation holder shall notify the competent authorities of any new information which 609 may impact the risk-benefit balance of a medicinal product [REG Art 16(2) and DIR 23(2)]. The need

- 610 for any subsequent communication, e.g. a DHPC, in the EU should be considered and agreed on a
- 611 case-by-case basis.
- A flow chart describing the processing of DHPCs is provided in Figure XV.I. at the end of the Module.

613 XV.C.2.2. Translation and dissemination of DHPCs

For centrally authorised <u>medicinal products</u>, <u>medicinal products</u> subject to an EU referral procedure for
 safety reasons and, in most cases, for <u>medicinal products</u> authorised through the mutual recognition or
 decentralised procedure, the working language for preparing the DHPCs will normally be English.


Once the text of the DHPC is agreed, the marketing authorisation holder should prepare translations in
the official languages of the Member States, as specified by the Member States where the DHPC is to
be distributed. The draft translations should be submitted to the Member States for a language review
within a reasonable timeframe (no more thanwhich should not exceed two 4-5 working days). Member
States should aim at reviewing the translations ideally within 48 hours.

622 For centrally authorised <u>medicinal products and medicinal products subject to an EU</u> referral procedure

623 for safety reasons, the relevant marketing authorisation holder should provide the Agency with a
624 complete set of all final EU official language versions as well as any additional related communication
625 documents.

626 XV.C.2.3. Publication of DHPCs

The competent authorities may publish the final DHPC. <u>The marketing authorisation holder will be</u>
<u>informed of the intent to publish the DHPC so that</u><u>+</u>the timing for such publication should beis aligned
to that of the dissemination of DHPC in the Member States. The competent authorities <u>in the Member</u>
<u>States</u> may also issue an additional safety announcement<u>(see XV.B.5.2.)</u>, and disseminate the<u>mir</u>
<u>DHPC</u> to relevant healthcare professionals' organisations as appropriate.



¹ The Agency will coordinate the review of DHPC within its scientific committees (i.e. PRAC and CHMP) and CMDh.

632

633 Figure $\forall X \underline{V}$.1: Flow chart for the processing of Direct Healthcare Professional Communications 634 (DHPCs) in the EU

635

636 GVP Annex II – Templates: Direct Healthcare Professional 637 Communication⁴

- 638 <u>Note</u>: This is an identical replication of GVP Annex II Templates: DHPC Rev 1 (EMA/36988/2013 639 Rev 1) in this Module for ease of reference.
- 640 <Date>

641 **Active substance, name of medicinal product and main message**

- 642 (e.g. introduction of a warning or a contraindication)>
- 643 Dear Healthcare professional,
- <Name of marketing authorisation holder> in agreement with <the European Medicines Agency>
 and the <National Competent Authority > would like to inform you of the following:

646 Summary

- 647 *Guidance*: This section should be in bold/larger font size than the other sections of the DHPC and 648 preferably in bullet points.
- <Brief description of the safety concern in the context of the therapeutic
 indication, recommendations for risk minimisation (*e.g. contraindications, warnings, precautions of use*) and, if applicable, switch to alternative treatment>
- <Recall information, if applicable, including level (pharmacy or patient) and date of recall>
- 654 Background on the safety concern
- 655 <u>Guidance</u>: This section may include the following information:
- 656 <Brief description of the therapeutic indication of the medicinal product>
- 657 <Important details about the safety concern (adverse reaction, seriousness, statement on the
- suspected causal relationship, and, if known, the pharmacodynamic mechanism, temporalrelationship, positive re-challenge or de-challenge, risk factors)>
- <An estimation of the frequency of the adverse reaction or reporting rates with estimated patientexposure>
- <A statement indicating any association between the adverse reaction and off-label use, ifapplicable>
- 664 <If applicable, details on the recommendations for risk minimisation>
- 665 <A statement if the product information is to be or has been revised, including a description of the
- 666 changes made or proposed> <u>Guidance:</u> No need however to include or attach the precise
- (translated) text of the product information which, at the time of dissemination of the DHPC may
- 668 *not be available as final approved translations)*
- 669 <Place of the risk in the context of the benefit>
- 670 <The reason for disseminating the DHPC at this point in time>
- 671 <Any evidence supporting the recommendation (e.g. include citation(s) of key study/ies)>

⁴ The current template should also be used for the preparation of a -core EU DHPC- (see XV.C.2.1.).

- 672 <A statement on any previous DHPCs related to the current safety concern that have recently been
- 673 disseminated>
- 674 <Any schedule for follow-up action(s) by the marketing authorisation holder/competent authority,</p>675 if applicable>

676 Call for reporting

- 677 <A reminder of the need and how to report adverse reactions in accordance with the national
- spontaneous reporting system, including the details (e.g. name, postal address, fax number,
 website address) on how to access the national spontaneous reporting system->
- 680 <
 680
 681 details>.
- 682 <Mention if product is subject to additional monitoring and the reason why>

683 Company contact point

<Contact point details for access to further information, including relevant website address(es),
 telephone numbers and a postal address>

686 **Annexes** (if applicable)

- <Link/reference to other available relevant information, such as information on the website of a
 competent authority>
- 689 <Additional scientific information, if applicable>
- 690 <List of literature references, if applicable>
- 691
- 692

693 GVP Annex II – Templates: Communication Plan for Direct Healthcare 694 Professional Communication

695 <u>Note</u>: This is an identical replication of GVP Annex II – Templates: Communication Plan for DHPC
696 (EMA/334164/2015) in this Module for ease of reference.

DHPC COMMUNICATION PLAN						
Medicinal product(s)/active substance(s)	NFLAN					
Marketing authorisation holder(s)	In cases where the DHPC concerns several marketing authorisation holders of the same active substance or is part of a class review, it is strongly encouraged that a single consistent message is sent to healthcare professionals in each EU Member State.					
	All concerned marketing authorisation holders in each Member State are strongly encouraged to collaborate, so that a single DHPC is prepared and circulated in each Member State. The letter circulated in each Member State should cover all active substance-containing products authorised in that Member State.					
	It is encouraged that the originator marketing authorisation holder (where available) in each Member State acts as the contact point for the national competent authority, on behalf of the other concerned marketing authorisation holders in the same Member State. If no originator product is marketed in the Member State, it is encouraged that one of the concerned generic companies acts as contact point for the competent authority.					
Safety concern and purpose of the communication	Consider using the title of the DHPC to describe the safety concern					
DHPC recipients	List all <u>(groups of)</u> recipients of the DHPC in this section, e.g. general practitioners, specialists, <u>community</u> pharmacists, <u>hospital pharmacists</u> , nurses, professional societies, national associations.					
Member States where the DHPC will be distributed						
Timetable Delete steps	which are not applicable	Date				
DHPC and communicat	ion plan (in English) agreed by PRAC					
DHPC and communicat	ion plan (in English) agreed by CHMP/CMDh					
Submission of translated DHPCs to the national competent authorities for review						
Agreement of translations by national competent authorities						
Dissemination of DHPC						